Phase II Pilot Study Evaluating the Efficacy of Dual Therapy With Raltegravir Plus Maraviroc in Patients Receiving Suppressive Antiretroviral Therapy and Presenting With Lipohypertrophy (ANRS 157 ROCnRAL).
Phase of Trial: Phase II
Latest Information Update: 22 Sep 2015
At a glance
- Drugs Maraviroc (Primary) ; Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms ROCnRAL
- 07 Jun 2017 Biomarkers information updated
- 22 Sep 2015 Results published in the Journal of Antimicrobial Chemotherapy.
- 30 Apr 2013 Last checked against ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History